Autotelic Bio
PrivateLast Round
Series B
Extension
Jun 29, 2026
Total Funding Raised
$22.18M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Autotelic Bio operates in Healthcare & Life Sciences and is based in South Korea. Its latest recorded funding round was a Series B Extension round in June 2026.
Autotelic Bio is a biotechnology company that develops innovative anti-cancer drugs and antisense oligonucleotide (ASO) therapeutics for the treatment of rare and incurable diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Autotelic Bio Comparables
Compare Autotelic Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secarna Pharmaceuticals | 85% | |
| Genetic Leap | 81% | |
| Creyon Bio | 81% |
For institutional investors. Book with your work email.
Autotelic Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 29, 2026 | ||||
| Series B | Mar 28, 2022 | ||||
| Strategic | Dec 14, 2020 | ||||
| Series A | Feb 1, 2020 | ||||
| Angel | Aug 1, 2018 |
For institutional investors. Book with your work email.
Autotelic Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KIWOOM Securities Co., Ltd. | Series B Extension |
| UTC Investment | Series A, Series B |
| Colopl Next | Series B |
| JB Investment | Series A, Series B, Series B Extension |
| Stonebridge Ventures | Series A, Series B |
| ROI Investment Partners | Series B |
| LSK Investment | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 29, 2026
Raised Series B Extension with investors JB Investment, Vine Ventures, and KIWOOM Securities.
- Mar 28, 2022
$13M round with participation from Dreamstone Partners and JB Investment.
For institutional investors. Book with your work email.
Autotelic Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Autotelic Bio's valuation, stock price, and market status.
Is Autotelic Bio a public or private company?
Autotelic Bio is a private company.
What is the current stock price of Autotelic Bio?
Autotelic Bio is a private company, so its shares have no public market price. Caplight tracks Autotelic Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Autotelic Bio worth (valuation)?
Valuation information for Autotelic Bio is not publicly available.
Can I buy Autotelic Bio stock?
Autotelic Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Autotelic Bio's last funding round?
Autotelic Bio's most recent funding round was Series B Extension on June 29, 2026.
Who are the main investors in Autotelic Bio?
Key investors in Autotelic Bio include KIWOOM Securities Co., Ltd., UTC Investment, Colopl Next, JB Investment, Stonebridge Ventures.
Will Autotelic Bio IPO soon?
No public IPO plans have been announced for Autotelic Bio.
How can I track Autotelic Bio secondary market activity?
Caplight tracks bids, offers, and trades in Autotelic Bio's shares on secondary markets.